Cancer characteristics in Lynch syndrome: a retrospective study in a large cohort of patients
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S460-S461
DOI: 10.1055/s-0044-1783864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von P. Cortegoso Valdivia und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Lynch syndrome (LS) is an inherited cancer syndrome associated with specific DNA mismatch repair (MMR) defects, accounting for a high risk of developing gastrointestinal (GI) and extra-GI cancers. The aim of this study is to comprehensively analyze the clinical and genetic features of a large cohort of LS patients focusing on mutation profiles and the distribution of GI cancers, including extra-GI ones.
Methods
We performed a retrospective analysis of LS patients followed at our center, from 2000 to 2023. MMR mutation distribution, demographic data, and cancer distribution were analyzed.
Results
57 patients (28 males, 49.1%) with a mean age of 63.5 years (range 21-91) were included with a mean follow-up of 20.8 years/patient. MMR mutations were available in 44 patients, distributed as follows: MLH1, 25 (43.8%); MSH2, 9 (15.7%); MSH6, 4 (7%); MSH2-MSH6, 4 (7%); MSH2-PMS2, 1 (1.7%); MLH1-PSM2, 1 (1.7%); 13 patients met Amsterdam II clinical criteria . 41 patients (71.9%) developed cancer, with a mean age of 43 years (range 21-62) at the first onset. GI cancer was the first neoplasm to be diagnosed in 87.8% of these patients. 16 patients remained cancer-free until evaluation, with a mean age of 51 years. Overall, 36 of 41 patients developed 68 GI cancers, including 27 metachronous cancers (mean age at first onset, 43.6 years [range 21-62]): colon 52 (76.4%), small bowel 10 (14.7%), rectum 3 (4.4%), and stomach 3 (4.4%). Regarding the first colon cancer, considering the entire population, the right colon was most affected (63.3%), primarily associated with MLH1 mutations (12/19 cases). The left colon was affected in 16.6%, with MSH2-MSH6 and MLH1 as the most frequent mutations . Almost half of surgically-treated colon cancers (46%) had pT3N0M0 staging. Only 3/41 patients developed metastases with an average follow-up time of 36 years since the first tumor. Metachronous GI cancers occurred in 18 patients, with a 12.5-year interval from the first tumor onset. MLH1 was the most frequently involved mutation (38.8%). Extra-GI cancers occurred in 26 patients, uterus (28%) and breast (24%) being the most common sites. MLH1 was the most frequently involved mutation (52%). 8 patients (13.8%) died at a mean age of 75.5 years (range 64-91) with a median follow-up of 26.75 years/patient. Causes of death included metastatic colon cancer (2/8), jejunal cancer (1/8), extra-GI cancer (3/8), multiple tumors (1/8) and cardiovascular disease (1/8).
Conclusions
Our study confirms the tendency of LS patients to develop early-onset cancers, especially in the GI tract which is the most affected site of first tumor onset, with a considerable cancer-related mortality. MLH1 is the most involved mutation in both GI and extra-GI cancers. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Valdivia, P. C., Mistretta, G., Pitoni, D., & Pennazio, M. (2024). Cancer characteristics in Lynch syndrome: a retrospective study in a large cohort of patients. Endoscopy, 56(S 02 S 02), S460-S461. https://doi.org/10.1055/s-0044-1783864
Vancouver
Valdivia PC, Mistretta G, Pitoni D, Pennazio M. Cancer characteristics in Lynch syndrome: a retrospective study in a large cohort of patients. Endoscopy. 2024;56(S 02 S 02):S460-S461. doi:10.1055/s-0044-1783864
BibTeX
@article{Valdivia2024,
author = {Valdivia, P. Cortegoso and Mistretta, G. and Pitoni, D. and Pennazio, M.},
title = {Cancer characteristics in Lynch syndrome: a retrospective study in a large cohort of patients},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S460--S461},
doi = {10.1055/s-0044-1783864}
}
EUVIMED